Breast Cancer Awareness Scrubs

For example, an increased risk of recurrent breast cancer has in particular been linked to obesity and diabetes in women. Breast Cancer Awareness Scrubs Other possible explanations for high levels of insulin are thought to act as a stimulus for cancer cells grow and divide. Other molecules associated with diabetes also appear to cause increased proliferation of cancer cells, or growth, including growth factor similar to insulin (IGF).

Metformin, also known as Glucophage, has become the most commonly prescribed oral medication for the treatment of diabetes. laboratory and public health studies have suggested that metformin may also be able to suppress the proliferation of cancer cells and reduce the risk of death from cancer. However, until now, there has been little direct evidence of clinical research to support this hypothesis.

A new clinical research study, just published in the Journal of Clinical Oncology, sheds further light on the potential role of metformin as a possible treatment for breast cancer new. In this retrospective study of clinical MD Anderson Cancer Center, the medical records of 2529 patients who received chemotherapy as initial treatment (neoadjuvant chemotherapy) for early stage breast cancer between 1990 and 2007 were examined. This group of patients with breast cancer, 68 patients with diabetes who took metformin, 87 diabetic patients not taking metformin, and 2374 patients without diabetes. All 2529 patients subsequently undergoing surgery for their breast cancer, and researchers then assessed the response of breast cancer for each woman to their initial chemotherapy.

Lung Cancer Secrets Revealed Click Here

A complete pathological response to chemotherapy occurs when the pathologist can not find any evidence of residual cancer after surgical removal of cancer of the original site. (Typically, a complete pathological response to neoadjuvant chemotherapy is associated with better prognosis.) Impact of pathological complete response to neoadjuvant chemotherapy was then evaluated in three groups of women involved in this trial.

In this study, women with diabetes who took metformin were found at three times the rate of pathological complete response to neoadjuvant chemotherapy than women with diabetes who were not taking metformin (there was no statistically significant difference between diabetic women taking metformin and non-diabetic women, but there was always a tendency to improve the pathological complete response in the metformin group).

Although the retrospective nature of this study and the relatively small number of diabetic women included in the study limits the conclusions that can be drawn, these results are consistent with other findings of previous research. Taken together, these data strongly suggest that metformin may be able, at least, offset the effects of diabetes on the proliferation of breast cancer cells. This raises the question of whether or not women with diabetes who are diagnosed with breast cancer should be routinely placed on metformin in the course of their cancer treatment program in general. Since this clinical study also detected a nonsignificant improvement in pathological complete response rates in diabetic women taking metformin, compared with women without diabetes, large prospective studies of clinical research may also help us understand whether or not metformin may be clinically useful in the treatment of breast C.